Clinical Pathway Discloses One Surgeon's $425 Habit

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 6
Volume 5
Issue 6

PHILADELPHIA--When practice guidelines or pathways take financial considerations into account, they may be termed clinical financial pathways (CFPs). This technique was developed by Kent Giles, MPPM, vice president of development at PhyMatrix, a physician management company headquartered in West Palm Beach, Fla, and is currently being utilized by PhyMatrix to reduce unnecessary medical costs.

PHILADELPHIA--When practice guidelines or pathways take financialconsiderations into account, they may be termed clinical financialpathways (CFPs). This technique was developed by Kent Giles, MPPM,vice president of development at PhyMatrix, a physician managementcompany headquartered in West Palm Beach, Fla, and is currentlybeing utilized by PhyMatrix to reduce unnecessary medical costs.

Developing CFPs involves seven steps, Mr. Giles said at the Associationof Cancer Executives meeting (see also page 20): Select a diseaseprocess, form a knowledgeable team, clarify the current stateof medical knowledge, develop the pathway, assign costs to eachprocess, implement the pathway, and monitor the results.

During development of the prostate CFP, he said, the team foundthat one urologist was using three surgical trays per radicalprostatectomy to access the three instruments he needed, sincethe hospital routinely placed only one of these instruments onthe surgical tray.

This practice, which added $425 in unnecessary costs for extrasterilization and wasted anesthesiologist and surgeon time, waseliminated with implementation of the CFP, and the patient's timeunder anesthesia was reduced by 30 minutes, ie, a quality enhancement.

Recent Videos
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
It may be crucial to test every patient for markers such as BRAF V600E mutations, NRG1 fusions, and KRAS G12C mutations to help manage pancreatic cancers.
4 KOLs are featured in this series.
Tanios S. Bekaii-Saab, MD, emphasizes the idea of moving targeted therapies to earlier lines of treatment to further improve outcomes in pancreatic cancer.